Cocrystal Pharma, Inc. - COCP STOCK NEWS

Cocrystal Pharma (Nasdaq: COCP) announced its participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A webcast of the presentation will be available on January 10, 2022, at 7:00 a.m. ET. The company aims to initiate first-in-human studies for two SARS-CoV-2 antivirals targeting COVID-19 and is progressing with its influenza A Phase 1 trial. Cocrystal is well positioned financially with a solid cash position and a debt-free balance sheet, allowing it to advance its clinical plans.

Cocrystal Pharma (Nasdaq: COCP) announced significant progress in combating COVID-19, confirming its protease inhibitors' efficacy against the Omicron variant and other strains. The company plans to initiate Phase 1 clinical studies for its intranasal and oral COVID-19 protease inhibitors, CDI-45205 and another yet-to-be-named oral inhibitor, shortly. Their inhibitors have exhibited broad-spectrum activity and promising safety profiles in preclinical studies, displaying no cytotoxicity and good bioavailability.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that President and interim CEO Sam Lee and CFO James Martin will present a company overview during the Noble Capital Markets Virtual Roadshow on December 8, 2021. The presentation will discuss Cocrystal's progress towards initiating clinical studies in 2022 for two COVID-19 protease inhibitors, which have shown broad-spectrum activity against variants including Delta. The company awaits FDA feedback on its IND briefing for its intranasal COVID-19 inhibitor and plans to submit another for its oral inhibitor in early 2022.

Cocrystal Pharma (Nasdaq: COCP) unveiled its clinical plans for two antiviral compounds targeting COVID-19 at the World Antiviral Congress 2021. The company presented promising preclinical data on CDI-45205, an intranasal lead, and oral protease inhibitors. The Phase 1 and Phase 2 trials are expected to assess safety and efficacy, focusing on the treatment of mild to moderate COVID-19. Cocrystal's inhibitors demonstrated broad-spectrum antiviral activity against multiple SARS-CoV-2 variants. The company is awaiting FDA feedback on its pre-IND briefing package.

Cocrystal Pharma (Nasdaq: COCP) reported no revenues for Q3 2021, down from $489,000 a year ago. R&D expenses rose to $2.2 million, primarily due to advancements in COVID-19 and influenza programs. The net loss widened to $3.9 million, or $0.04 per share, compared to a loss of $2.7 million, or $0.05 per share, in Q3 2020. For the first nine months of 2021, the company reported no revenues versus $1.5 million in 2020, while R&D expenses increased 22% to $6.5 million. They have $61.6 million in cash and aim to advance multiple antiviral compounds into clinical development by 2022.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that its SARS-CoV-2 main protease inhibitors exhibit strong in vitro activity against various common viruses, including rhinoviruses and noroviruses. These inhibitors were developed using proprietary drug discovery technology and are advancing towards clinical trials as potential COVID-19 treatments. President Sam Lee highlighted the significance of these drugs as potential oral therapies and expressed optimism for addressing other viral diseases.

Cocrystal Pharma (Nasdaq: COCP) has submitted a pre-Investigational New Drug briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205, aiming to treat COVID-19. The submission seeks FDA guidance on clinical trial design, including preclinical studies and toxicology assessments. CDI-45205 has demonstrated potent in vitro activity against multiple SARS-CoV-2 variants and is being developed for various administration routes, with a focus on intranasal delivery. Cocrystal believes its targeted approach may offer a superior treatment solution compared to repurposed drugs.

Cocrystal Pharma (Nasdaq: COCP) announced that President Dr. Sam Lee will present new data from its COVID-19 programs at the World Antiviral Congress 2021 in San Diego on December 1, 2021, at 11:55 a.m. PST. He will discuss the discovery of oral broad-spectrum SARS-CoV-2 main protease inhibitors and advancing them to clinical development. Dr. Lee expressed gratitude for the opportunity to share exciting preclinical data regarding novel COVID-19 oral and intranasal protease inhibitors. A related press release will accompany the presentation.

Cocrystal Pharma (Nasdaq: COCP) will present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021, at 2:00 p.m. ET in Jupiter, Florida. The company recently received regulatory clearance from an Australian Human Research Ethics Committee to start a Phase 1 trial for its orally administered CC-42344 drug targeting influenza A. CFO James Martin expressed enthusiasm for discussing the company's COVID-19 antiviral programs during the presentation. A live and archived webcast will be available on the company's website.